Hepatitis B Floor Antigen Seroclearance in HBV Unlikely With Entecavir, Tenofovir

by admin

Sufferers with continual hepatitis B virus (HBV) an infection who’re handled with entecavir or tenofovir disoproxil fumarate have been discovered to have low seroclearance of hepatitis B floor antigen (HBsAg), in keeping with examine outcomes printed in The Journal of Infectious Ailments. The outcomes of this examine additionally advised that baseline components that will predict HBsAg seroclearance embrace low ranges of viremia, a flare in alanine transaminase, serum bilirubin ranges, and fatty liver.

Though antiviral therapy with nucleoside/nucleotide analogues has been proven to cut back the chance of medical complication in sufferers with continual HBV an infection, steady therapy to beat drug resistance is usually wanted for continued viral remission. For sufferers handled with nucleoside/nucleotide analogue therapies, HBsAg seroclearance is linked to improved medical outcomes and off-therapy remission; nonetheless, such outcomes are uncommon with short-term remedy, and the results that long-term nucleoside/nucleotide analogues have on HBsAg seroclearance are unclear.

A workforce of investigators carried out a global, multicenter, retrospective cohort examine of sufferers with continual HBV an infection to deal with these data gaps by figuring out the incidence of HBsAg seroclearance, how that incidence would possibly change over time, and what baseline components would have an effect on HBsAg seroclearance in sufferers on long-term remedy.

Proceed Studying

A complete of 4769 treatment-naive sufferers (median age, 50 years; 69.05% males; 88.78% Asian) who didn’t have any malignancies firstly of the examine have been handled with both entecavir (84.25%) or tenofovir (15.75%). HBsAg seroclearance was recorded till demise or loss attributable to follow-up with a median follow-up of 5.16 years.

Of the cohort, 58 (1.22%) of the sufferers had HBsAg seroclearance, and 213 sufferers died previous to HBsAg seroclearance. The ten-year cumulative incidence of HBsAg seroclearance was low (2.11%), and the annual incidence averaged 0.22% per yr. There have been no important developments noticed for price adjustments over time (P =.93).

Within the ultimate statistical mannequin generated, baseline components that affected the probability of HBsAg seroclearance included low-level viremia with HBV DNA of lower than 2000 IU/mL (adjusted subdistribution hazard ratio [aSHR], 3.14), elevated alanine transaminase of greater than 200 U/L (aSHR, 3.68), serum bilirubin (aSHR, 1.11 per mg/dL), and fatty liver (aSHR, 1.84).

“These findings point out HBsAg seroclearance is a distant and even unrealistic endpoint of the present antiviral technique, whereas offering a practical reference level for future HBV treatment medical trial design,” the examine authors concluded.

Disclosure: Some examine authors declared affiliations with biotech, pharmaceutical and/or system firms. Please see the unique article for a full checklist of authors’ disclosures.


Hsu Y-C, Yeh M-L, Wong GL-H, et al. Incidences and determinants of purposeful treatment throughout entecavir or tenofovir disoproxil fumarate for continual hepatitis B. J Infect Dis. Printed on-line Might 17, 2021. doi:10.1093/infdis/jiab241

Supply hyperlink

You may also like

Leave a Comment